Notification of delay of decision on denosumab funding proposal

Update Medicines

PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to fund denosumab 60 mg prefilled syringed for the treatment of osteoporosis.

PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to fund denosumab 60 mg prefilled syringed for the treatment of osteoporosis.

The proposal was the subject of a consultation dated 16 March 2018.

Consultation on this proposal closed on 4 April. Some significant issues were raised in consultation responses and we require additional time to consider them before a decision can be made on the proposal.

This delay will mean that a decision will not be made in time to implement the proposed funding changes by 1 June 2018. We do not currently have a firm timeframe for when a decision will be made on this proposal.

If you have any questions about this notification, please contact Alexander Rodgers, Therapeutic Group Manager, by email at alexander.rodgers@pharmac.govt.nz